Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles BMC Infectious Diseases Year : 2014

Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients

Domains

Infectious diseases
Fichier principal
Vignette du fichier
1471-2334-14-S2-P84.pdf (52.48 Ko) Télécharger le fichier
1471-2334-14-S2-P84.xml (5.29 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Ed. BMC  : Connect in order to contact the contributor

https://www.hal.inserm.fr/inserm-00995737

Submitted on : Friday, May 23, 2014-5:14:14 PM

Last modification on : Friday, March 24, 2023-2:52:58 PM

Long-term archiving on: Monday, August 25, 2014-11:36:07 AM

Download

Dates and versions

inserm-00995737 , version 1 (23-05-2014)

Identifiers

  • HAL Id : inserm-00995737 , version 1

Cite

Amélie Ménard, Catherine Dhiver, Isabelle Ravaux, Jacques Moreau, Saadia Mokhtari, et al.. Efficacy and safety of hepatitis C direct-acting protease inhibitors (DAA-PI ) in real life in HIV-HCV coinfected patients. BMC Infectious Diseases, 2014, 14 (Suppl 2), pp.P84. ⟨inserm-00995737⟩

Export

BibTeX TEI Dublin Core DC Terms EndNote Datacite

Collections

INSERM IRD CNRS UNIV-AMU
82 View
114 Download

Share

Gmail Facebook Twitter LinkedIn More